Evidence map›Paper›PMID 39347515›Full record

ArticleThe application of clinical genetics2024

Class II Transactivator Gene (

Omaima Abdel Majeed Mohamed Salih, Nahla Hashim Hassan Erwa, Abdelrahman Hamza Abdelmoneim, Hiba Awadelkareem Osman Fadl, Brigitte Glanzmann, Manasik Abdalla Babiker Osman, Monzir Ahmed Hassan Osman, Thuraya Mohamed Elshiekh Gasim, Alamin Mustafa

Abstract readCase Reports
In one paragraph

Article in The application of clinical genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Omaima Abdel Majeed Mohamed SalihDepartments of Pediatrics, Faculty of Medicine, Omdurman Islamic University, Omdurman, Sudan.
Nahla Hashim Hassan ErwaClinical Immunology Consultant, Faculty of Medicine & Soba University Hospital, University of Khartoum, Khartoum, Sudan.
Abdelrahman Hamza AbdelmoneimFaculty of Medicine, Al-Neelain University, Khartoum, Sudan.ORCID 0000-0002-5037-8488
Hiba Awadelkareem Osman FadlDepartment of Hematology, Faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan.ORCID 0000-0002-3614-1994
Brigitte GlanzmannDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, 7505, South Africa.
Manasik Abdalla Babiker OsmanFaculty of Medicine, University of Bahri, Khartoum, Sudan.
Monzir Ahmed Hassan OsmanFaculty of Medicine and Health Sciences, Omdurman Islamic University, Khartoum, Sudan.
Thuraya Mohamed Elshiekh GasimFaculty of Medicine and Health Sciences, Omdurman Islamic University, Khartoum, Sudan.
Alamin MustafaFaculty of Medicine, Al-Neelain University, Khartoum, Sudan.ORCID 0000-0003-1129-6284

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Inborn errors of immunity (IEI) are disorders that present a health issue, especially in developing countries where there is a high rate of consanguineous marriages and an increasing rate of diagnosis. One of these disorders is Bare Lymphocyte Syndrome II (BLS II) which is a rare and genetically complex disease that has high morbidity and mortality. The exact genotypic and phenotypic characteristics are still poorly characterized especially in developing countries. Case Presentation: Here, we report the first case of BLS II in a seven-month-old Sudanese female with recurrent chest infections, dermatitis, persistent diarrhea, and failure to thrive. The patient's all four sisters and three paternal uncles died in early infancy. Laboratory investigations revealed low CD3+, CD4+, and CD8+ lymphocytes, along with normal CD19+ and CD16+ lymphocytes, and low serum IgM and IgA levels. Genetic analysis revealed two Conclusion: Further bioinformatics, immunological and clinical workups supported a pathogenic effect of both mutations affecting the function of CIITA protein, and suggesting a compound heterozygote mutation. The patient was started on prophylactic antibiotics and regular intravenous immunoglobulin replacement therapy. The prognosis of this disease is poor in most of the cases, with only a few reported cases surviving until adulthood.

Indexed as

bare lymphocyte syndrome IICIITA genecompound heterozygote mutationinborn errors of immunityprimary immunodeficiency

Identifiers

PMID39347515
PMCPMC11430264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.